Molecular Formula | C38H65NO14 |
Molar Mass | 759.93 |
Density | 1.22±0.1 g/cm3(Predicted) |
Melting Point | >135°C (dec.) |
Boling Point | 859.8±65.0 °C(Predicted) |
Flash Point | 473.8°C |
Solubility | Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly) |
Vapor Presure | 1.91E-34mmHg at 25°C |
Appearance | Solid |
Color | White |
pKa | 13.49±0.70(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.534 |
In vitro study | Erythromycin is used in treatment of respiratory, gastrointestinal, and genital tract infections, as well as skin and soft tissue infections. Erythromycin, with its ten chiral centers and two sugar substituents (L-cladinose and D-desosamine), is a good starting point for numerous medicinal chemistry efforts for improvement of its biological profile (better activity, higher stability, and improved bioavailability) since the first generation of macrolides, which had low toxicity and good tolerability, are unstable in acidic media, had low toxicity and good tolerability. |
Toxicity | LD50 oral in rat: 5800mg/kg |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.316 ml | 6.58 ml | 13.159 ml |
5 mM | 0.263 ml | 1.316 ml | 2.632 ml |
10 mM | 0.132 ml | 0.658 ml | 1.316 ml |
5 mM | 0.026 ml | 0.132 ml | 0.263 ml |